Key Details
Annual EPS
-$0.14Annual ROE
-29.50%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 10, 2023Recent annual earnings:
May 25, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with TYME included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Tyme Technologies doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Tyme Technologies?
- What is the ticker symbol for Tyme Technologies?
- Does Tyme Technologies pay dividends?
- What sector is Tyme Technologies in?
- What industry is Tyme Technologies in?
- What country is Tyme Technologies based in?
- When did Tyme Technologies go public?
- Is Tyme Technologies in the S&P 500?
- Is Tyme Technologies in the NASDAQ 100?
- Is Tyme Technologies in the Dow Jones?
- When was Tyme Technologies's last earnings report?
- When does Tyme Technologies report earnings?
What is the primary business of Tyme Technologies?
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
What is the ticker symbol for Tyme Technologies?
The ticker symbol for Tyme Technologies is NASDAQ:TYME
Does Tyme Technologies pay dividends?
No, Tyme Technologies does not pay dividends
What sector is Tyme Technologies in?
Tyme Technologies is in the Healthcare sector
What industry is Tyme Technologies in?
Tyme Technologies is in the Biotechnology industry
What country is Tyme Technologies based in?
Tyme Technologies is headquartered in United States
When did Tyme Technologies go public?
Tyme Technologies's initial public offering (IPO) was on 25 May 2012
Is Tyme Technologies in the S&P 500?
No, Tyme Technologies is not included in the S&P 500 index
Is Tyme Technologies in the NASDAQ 100?
No, Tyme Technologies is not included in the NASDAQ 100 index
Is Tyme Technologies in the Dow Jones?
No, Tyme Technologies is not included in the Dow Jones index
When was Tyme Technologies's last earnings report?
Tyme Technologies's most recent earnings report was on 10 February 2023
When does Tyme Technologies report earnings?
The date for Tyme Technologies's next earnings report has not been announced yet